Search Browse Earnings

Zhengye Biotechnology Holding Ltd — SlamSEC

Zhengye Biotechnology Holding Ltd

Nasdaq:ZYBT

Pharmaceutical Preparations·JILIN

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$25.5M

FY 2024

Adj. EBITDA

$5.6M

21.8% margin

FY 2024

Net Income

$1.6M

6.1% margin

FY 2024

EPS (Diluted)

$0.03

FY 2024

Stock Price

$0.77

+1.2%

2026-03-12

52W Range

$0.70 – $14.30

P/E Ratio

25.7x

Market Cap

$35.3M

Cash

$2.5M

FY 2024

Total Debt

$10.9M

FY 2024

Net Debt

$8.3M

FY 2024

Enterprise Value

$43.6M

Debt / EBITDA

1.5x

FY 2024

EV / EBITDA

7.8x

Employees

—